
    
      The primary objective of this study was to determine clinical benefit rate (CBR) i.e.complete
      remission (CR) + partial remission (PR) + stable disease (SD) lasting â‰¥ 6 months, and the
      toxicity of RAD001 /carboplatin in women with metastatic triple-negative breast cancer.
      Treatment consisted of intravenous carboplatin at area under the plasma concentration-time
      curve (AUC) 6, later decreased to AUC 5, and subsequently to AUC 4 every 3 weeks with daily
      5mg RAD001.
    
  